Hexamitiasis leads to lower metabolic rates in rainbow trout Oncorhynchus mykiss (Walbaum) juveniles

© 2013 John Wiley & Sons Ltd.

Détails bibliographiques
Publié dans:Journal of fish diseases. - 1998. - 37(2014), 12 vom: 25. Dez., Seite 1013-20
Auteur principal: Ogut, H (Auteur)
Autres auteurs: Parlak, R
Format: Article en ligne
Langue:English
Publié: 2014
Accès à la collection:Journal of fish diseases
Sujets:Journal Article Research Support, Non-U.S. Gov't Hexamita salmonis infectious pancreatic necrosis virus metabolic activity metronidazole rainbow trout weight loss Antiparasitic Agents Metronidazole 140QMO216E
Description
Résumé:© 2013 John Wiley & Sons Ltd.
This study assessed the effects of Hexamita salmonis (Moore) on metabolism of rainbow trout Oncorhynchus mykiss (Walbaum) and its effect on the host's susceptibility to infectious pancreatic necrosis virus (IPNV) after antiparasitic treatment. Rainbow trout naturally infected with H. salmonis were treated with 10 mg metronidazole kg fish(-1) per day, and their physiological recovery was assessed through measuring resting metabolism on the 7th, 14th, 21st and 28th day after treatment. In addition, we exposed the naïve fish to H. salmonis and measured the resting metabolism (oxygen consumption as mg O2 kg(-1) per hour) on the 10th, 20th and 30th day after the exposure to assess the variation in metabolic rates after infection. Significantly lower rates of metabolic activity (P < 0.05) were anticipated 20 days after infection with H. salmonis compared with the fish infected with H. salmonis for 10 days or with the parasite-free fish. Similarly, the treated fish needed about 20 days to fully recover from hexamitiasis. The susceptibility of rainbow trout to IPNV remained unchanged in the presence of H. salmonis. Weight loss was significantly higher (P < 0.05) in infected than that in the parasite-free fish. Fish should be examined regularly for H. salmonis and treated immediately whether found to prevent economic losses and excessive size variation
Description:Date Completed 02.04.2015
Date Revised 30.09.2020
published: Print-Electronic
Citation Status MEDLINE
ISSN:1365-2761
DOI:10.1111/jfd.12188